Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...

Exelixis, Inc. EXEL announced that the District Court of Delaware has ruled in its favor in the second patent litigation ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

In addition to the legal success, Exelixis has received an upgrade from B of A Securities. The firm has maintained a Buy rating and raised the price target from $30 to $32. This optimistic outlook ...

Exelixis (EXEL) stock surged 7.3% after winning a patent battle against generic drug maker MSN Laboratories over Cabometyx.

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine therapy, according to ...

French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for use in England and Wales for previously treated ...

Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...